Online inquiry

IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14231MR)

This product GTTS-WQ14231MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14231MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1858MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ359MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ5637MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ11326MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ5500MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ7341MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ10461MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ12827MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW